Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Management of Bartholin’s cyst and abscess, Gynaecology (066)
Announcements and latest updates

Right Decision Service newsletter: September 2024

Welcome to the Right Decision Service (RDS) newsletter for September 2024.

1.Business case for permanent provision of the Right Decision Service from April 2025 onwards

This business case has now been endorsed by the HIS Board and will shortly be submitted to Scottish Government.

2. Management of RDS support tickets

To balance increasing demand with available capacity and financial resource, the RDS team and Tactuum are now working together to  implement closer management of support tickets. As a key part of this, we want to ensure clear, timely and consistent communication with yourselves as requesters.  

Editors will now start seeing new messages come through in response to support ticket requests which reflect this tightening up and improvement of our processes.

Key points to note are:

2.1 Issues confirmed by the RDS and Tactuum teams as meeting the critical/urgent and high priority criteria will continue to be prioritised and dealt with immediately.

Critical/urgent issues are defined as:

  1. The Service as a whole is not operational for multiple users. OR
  2. Multiple core functions of the Service are not operational for multiple users.

Example – RDS website outage.

Please remember to email ann.wales3@nhs.scot and his.decisionsupport@nhs.scot with any critical/urgent issues in addition to raising a support ticket.

High priority issues are defined as:

  1. A single core function of the Service is not operational for multiple users. OR:
  2. Multiple non-core functions of the Service are not operational for multiple users.

Example – Build to app not working.

2.2 Support requests that are outwith the warranty period of 12 weeks since the software was originally developed will not be automatically addressed by Tactuum. The RDS team will consider these requests for costed development work and will obtain estimate of effort and cost from Tactuum for priority issues.

2.3 Support tickets for technical issues that are not classified as bugs will not be automatically addressed by Tactuum. The definition of a bug is ‘a defect in the software that is at variance with documented user requirements.’  Issues that are not bugs will also be considered for costed development work.

The majority of issues currently in support tickets fall into category 2 or 3 above, or both.

2.4 Non-urgent requests that require a deployment (i.e a new release of RDS) will normally be factored into the next scheduled release (currently end of Nov 2024 and end of Feb 2025) unless by special agreement with the RDS team.

Please note that we plan to move in the new year to a new system whereby requests all come to an RDS support portal in the first instance and are triaged from there to Tactuum when appropriate.

We will be organising a webinar in a few weeks’ time to take you through the details of the current support processes and criteria.

3. Next scheduled deployment.

The next scheduled RDS deployment will take place at the end of November 2024.  We are reviewing all outstanding support tickets and feature requests along with estimates of effort and cost to determine which items will be included in this deployment.

We will update you on this in the next newsletter and in the planned webinar about support ticket processes.

4. Contingency arrangements for RDS

Many thanks to those of you who attended our recent webinar on the contingency arrangements being put in place to prevent future RDS outages as far as possible and minimise impact if they do occur.  Please contact ann.wales3@nhs.scot if you would like a copy of the slides from this session.

5. Transfer of CKP pathways to RDS

The NES clinical knowledge pathway (CKP) publisher is now retired and the majority of pathways supported by this tool have been transferred to the RDS. Examples include:

NHS Lothian musculoskeletal pathways

NHS Fife rehabilitation musculoskeletal pathways

NHS Tayside paediatric pathways

6. Other new RDS toolkits

Include:

Focus on frailty (from HIS Frailty improvement programme)

NHS GGC Money advice and support

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

To go live imminently:

  • Focus on dementia
  • NHS Lothian infectious diseases toolkit
  • Dumfries and Galloway Adult Support and Protection procedures
  • SIGN guideline – Prevention and remission of type 2 diabetes

 

7. Evaluation projects

We have recently analysed the results of a survey of users of the Scottish Palliative Care Guidelines toolkit.  Key findings from 61 respondents include:

  • Most respondents (64%) are frequent users of the toolkit, using it either daily or weekly. A further 25% use it once or twice per month.
  • 5% of respondents use the toolkit to deliver direct patient care and 82% use it for learning
  • Impact on practice and decision-making was rated as very high, with 80% of respondents rating these at a 4-5 on a 5 point scale.
  • Impact on time saving was also high, with 74% of respondents rating it from 3-5.
  • 74% also reported that the toolkit improved their knowledge and skills, rating these at 4-5 on the Likert scale

Key strengths identified included:

  • The information is useful, succinct, and easy to understand (31%).
  • Coverage is comprehensive (15%)
  • All information is readily accessible in one place and users value the offline access via mobile app (15%)
  • Information is reliable, evidence-based and up to date (13%)

Users highlighted key areas for improvement in terms of navigation and search functionality. The survey was very valuable in enabling us to uncover the specific issues affecting the user experience. Many of these can be addressed through content management approaches. The issues identified with search results echo other user feedback, and we are costing improvements with a view to implementation in the next RDS deployment.

8.RDS High risk prescribing (polypharmacy) decision support embedded in Vision and EMIS primary care E H R systems

This decision support software, sponsored by Scottish Government Effective Prescribing and Therapeutics Division,  is now available for all primary care clinicians across NHS Tayside. Board-wide implementation is also planned for NHS Lothian, and NHS GGC, NHS Ayrshire and Arran and NHS Dumfries and Galloway have initial pilots in progress. The University of Dundee has been commissioned to evaluate impact of this decision support software on prescribing practice.

9. Video tutorials for RDS editors

Ten bite-size (5 mins or less) video tutorials for RDS editors are now available in the “Resources for providers of RDS tools” section of the RDS.  These cover core functionality including Save and preview, content page and media management, password management and much more.

10. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Wednesday 23rd October 4-5 pm
  • Tuesday 29th October 11 am -12 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

 

Management of Bartholin’s cyst and abscess, Gynaecology (066)

Warning

Objectives

To provide guidance on the management of those presenting with and Bartholin’s cyst or abscess

Audience

All healthcare professionals involved in the care of women with a Bartholin’s cysts or abscess

Please report any inaccuracies or issues with this guideline using our online form

The Bartholin’s gland is a mucus secreting gland located bilaterally at the base of the labia minora, at the level of the hymen. When the duct becomes blocked, a cyst may form and the gland may be palpable. If the cyst becomes infected, an abscess may form which can cause severe pain. The life-time risk is approximately 3%. 

Clinical Features

Patients will present with a painful unilateral swelling in the vagina. 

On examination, there will be a tender, erythematous swelling at 4 or 8 o’clock on the lateral vaginal wall. Tracking of the abscess along the vaginal wall may cause cellulitis. 

Differential diagnosis

  • Inclusion cyst
  • Gartner duct cyst
  • Haematoma
  • Sebaceous cyst
  • Lipoma
  • Hidradenitis suppurativa
  • Endometriosis

Investigations

A charcoal swab should be obtained from the cyst/abscess and sent for culture and sensitivity. It is estimated that >70% of cysts are culture sterile, and only 33% of abscess cultures are sterile.

Bartholin’s duct abscesses may be polymicrobial: E. coli (single most common pathogen), followed by infections including Staphylococcus aureus, Group B streptococci and Enterococci species. Neisseria gonorrohoea may be identified.

Additional appropriate swabs should be obtained for chlamydia and gonorrohoea if there is risk of a sexually transmitted infection. 

Biopsy

A biopsy may be indicated in women over 40 years old as there is an increased risk of adenocarcinoma of the Bartholin’s gland. 

Management

This will depend on the severity and the duration of the patient’s symptoms in addition to patient preference.   

Recurrence rates are not consistently reported.  However, one RCT (WoMan trial) summarised that Marsupialisation and Word catheter recurrence at 12 months are similar (10-12%).   Where incision and drainage or needle aspiration is performed, recurrence is thought to be higher, and therefore should be avoided if possible.  The aim should being to create a new mucocutaneous junction between the wall of the cyst and the skin of the labia to allow continued drainage.

Conservative management, no signs of infection

Hot baths several times per day and simple analgesia.  In the absence of cellulitis, antibiotics are not indicated.

Conservative management, no surgical intervention with suggestion of mild infection with presence of cellulitis or offensive discharge.  A review of any previous swabs should be undertaken.

Where antibiotic treatment is required, suggested regimes are

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

Or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Surgical Management - Word Balloon Catheter

This treatment should be used first line in the surgical management of Bartholin’s cysts or abscesses. This is a very well tolerated procedure and has good operative success. 

The Word catheter kits contain the 3cm long catheter, a syringe for inflation and the scalpel. A local anaesthetic, such as 1% lidocaine, may be used to infiltrate the skin prior to the initial incision being made. Via a 5mm stab incision into the mucosal surface of the labia minora, just exterior to the hymen ring, within the introitus in the region of the normal duct opening. 

A charcoal swab should be obtained from the discharging fluid. 

The catheter is inserted and inflated with a maximum of 3ml of saline, as per the manufacturer’s guidelines. If the balloon is overfilled this may cause extra discomfort so the balloon should be deflated by extracting some saline. If the incision is made too large the catheter may fall out so an anchor suture may be required to hold it in place.

The patient can go home with the catheter in situ and usually this stays in for 4 weeks to encourage formation of an epithelialised fistula and prevent refilling of the abscess. A patient information leaflet should be given with a contact number for the gynaecology emergency service.

After 4 weeks, the catheter is deflated and removed. If the catheter falls out at home during this time it may be left out provided the patient’s symptoms are resolving. 

Where there are no signs of infection, antibiotic cover is not required.

Consideration should be made to cover with broad spectrum antibiotics if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis.  A review of any previous swab results should be undertaken.

Where antibiotic treatment is required suggest

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Surgical Management - Marsupialisation 

Where there is a recurrent abscess or if patient would prefer to avoid Word Catheter insertion, marsupialisation under a general anaesthetic should be performed. The purpose of this is to create a fistula and prevent further abscess formation. Packing is not routinely required. 

In theatre, a single dose of intravenous antibiotic cover should be given.

1.2g of co-amoxiclav, IV

or

900mg of clindamycin, IV

Consideration should be made to continue cover with broad spectrum antibiotics, particularly if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis. 

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Follow up

This is not routinely required after marsupialisation of the cyst or abscess.

If patients have already been commenced on oral antibiotics, they may wish to complete the course. However, they do not routinely need to start treatment after the initial dose in theatre, if there are no signs suggestive of infection.

Simple vulval hygiene advice should include avoiding bubble baths, lotions or talcum powder. Sexual intercourse should be avoided until there is no pain or discharge. 

Editorial Information

Last reviewed: 14/06/2023

Next review date: 16/05/2026

Author(s): Joy SimpsonDr Joy Simpson, Consultant O&G PRM.

Version: 2

Approved By: Gynaecology Clinical Governance Group

Document Id: 066

Related resources
References

Balloon catheter insertion for Bartholin's cyst or abscess | Guidance and guidelines | NICE

Inserting an inflatable balloon to treat a bartholin’s cyst or abscess Interventional Procedure guidance 323. December 2009. National Institute for Health and Clinical Excellence (NICE)

Wechter Wu, Marzano and Haefner. Management of bartholin duct cyst and abscesses. A systematic review. Obstetrical and Gynaecolocal Survey; 64(6) 2009. 

BMJ Best Practice, Bartholin's cyst - Symptoms, diagnosis and treatment, August 2022.

Omole F et al. Bartholin Duct Cyst and Gland Abscess: Office ManagementAm Fam Physician. 2019;99(12):760-766

Kroese AJ et al. Word catheter and marsupialisation in women with a cyst or abscess of the Bartholin gland (WoMan-trial): a randomised clinical trial. BJOG. 2017 Jan;124(2):243-249.